

REGENERON PHARMACEUTICALS INC

Form 8-K

December 21, 2007

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K  
CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15 (D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): December 21, 2007 (December 20, 2007)**

**REGENERON PHARMACEUTICALS, INC.**  
(Exact name of registrant as specified in its charter)  
**New York**  
(State or other jurisdiction of incorporation)

**000-19034**  
(Commission File No.)

**13-3444607**  
(IRS Employer Identification No.)

**777 Old Saw Mill River Road, Tarrytown, New  
York**  
(Address of principal executive offices)

**10591-6707**  
(Zip Code)

**(914) 347-7000**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
-

**TABLE OF CONTENTS**

Item 1.01. Entry Into a Material Definitive Agreement

Item 8.01. Other Events

Item 9.01 Financial Statements and Exhibits

SIGNATURE

Exhibit Index

EX-99.1: PRESS RELEASE

---

**Table of Contents**

**Item 1.01. Entry Into a Material Definitive Agreement.**

On December 20, 2007, as a condition to the closing of a stock purchase agreement by and among sanofi-aventis Amérique du Nord, sanofi-aventis US LLC (such companies and their affiliates, including sanofi-aventis and Aventis Pharmaceuticals Inc., being referred to herein as Sanofi ) and Regeneron Pharmaceuticals, Inc. (the Company ), the Company entered into an Investor Agreement with Sanofi. A brief description of the terms and conditions of the Investor Agreement that are material to the Company is set forth in the Form 8-K filed by the Company on November 29, 2007 under the heading *Equity Placement* in Item 1.01 of such Form 8-K, which description is incorporated by reference herein.

**Item 8.01. Other Events.**

On December 20, 2007, the Company issued a press release announcing that following early termination of the Hart-Scott-Rodino waiting period, the Company closed the sale of 12 million newly issued shares of Company common stock to Sanofi at a price of \$26.00 per share pursuant to its previously announced agreement. A copy of this press release is attached as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Document</b>
--------------------	-----------------

99.1	Press Release issued by the Company, dated December 20, 2007
------	--

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

REGENERON PHARMACEUTICALS, INC.

**Date:** December 21, 2007

**By:** /s/ Stuart Kolinski

**Name:** Stuart Kolinski

**Title:** Senior Vice President and General Counsel

---

**Table of Contents**

Exhibit Index

Number	Description
99.1	Press Release issued by the Company, dated December 20, 2007